{"id":"mt-7117-low-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MT-7117 directly activates soluble guanylate cyclase, an enzyme that produces cyclic guanosine monophosphate (cGMP), a key signaling molecule in vascular smooth muscle relaxation. By increasing cGMP levels, the drug promotes vasodilation and reduces pulmonary vascular resistance, making it potentially beneficial for pulmonary hypertension. The low-dose formulation is designed to optimize tolerability while maintaining therapeutic efficacy.","oneSentence":"MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:19.166Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension (PAH)"}]},"trialDetails":[{"nctId":"NCT03520036","phase":"PHASE2","title":"Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2018-07-05","conditions":"Erythropoietic Protoporphyria (EPP)","enrollment":102},{"nctId":"NCT04402489","phase":"PHASE3","title":"Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria","status":"COMPLETED","sponsor":"Tanabe Pharma America, Inc.","startDate":"2020-06-01","conditions":"EPP, XLP","enrollment":184}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dersimelagon"],"phase":"phase_3","status":"active","brandName":"MT-7117 low dose","genericName":"MT-7117 low dose","companyName":"Tanabe Pharma America, Inc.","companyId":"tanabe-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MT-7117 is a selective activator of the soluble guanylate cyclase (sGC) pathway that increases intracellular cGMP levels to promote vasodilation and reduce pulmonary vascular resistance. Used for Pulmonary arterial hypertension (PAH).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}